Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Chen, Hui ^a   Liu, Shuai ^b   Ji, Lu ^a   Wu, Tianfeng ^a   Ji, Yong ^b   Zhou, Yuying ^b   Zheng, Miaoyan ^c   Zhang, Meilin ^a   Xu, Weili ^d   Huang, Guowei ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Huanhu Hospital   (China)

^c Metabolic Diseases Hospital   (China)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIINFLAMMATORY AGENT; DONEPEZIL; FOLIC ACID; HOMOCYSTEINE; INTERLEUKIN 6; MEMANTINE; MESSENGER RNA; PRESENILIN; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; TUMOR NECROSIS FACTOR ALPHA; CYANOCOBALAMIN;

AGED; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; COGNITION; CONTROLLED STUDY; FEMALE; FOLIC ACID BLOOD LEVEL; FOLLOW UP; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VITAMIN SUPPLEMENTATION; ADULT; BLOOD; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; FOLIC ACID; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; VITAMIN B 12;

EID: 84975260913     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/5912146     Document Type: Article

References (48)

1. D. A. Evans, H. H. Funkenstein, M. S. Albert et al., "Prevalence of Alzheimer's disease in a community population of older persons, higher than previously reported," The Journal of the American Medical Association, vol. 262, no. 18, pp. 2551-2556, 1989.
2. K. Y. Chan, J. J. Wu, L. Liu et al., "Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis," The Lancet, vol. 381, no. 9882, pp. 2016-2023, 2013.
3. C. L. Masters, R. Cappai, K. J. Barnham, V. L. Villemagne, "Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics," Journal of Neurochemistry, vol. 97, no. 6, pp. 1700-1725, 2006.
4. L. Chouliaras, D. Mastroeni, E. Delvaux et al., "Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients," Neurobiology of Aging, vol. 34, no. 9, pp. 2091-2099, 2013.
5. D. Gezen-Ak, E. Dursun, H. Hanagas et al., "BDNF, TNF, HSP90, CFH, IL-10 serum levels in patients with early or late onset Alzheimer's disease or mild cognitive impairment," Journal of Alzheimer's Disease, vol. 37, no. 1, pp. 185-195, 2013.
6. U. N. Das, "Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, Alzheimer's disease-but how and why" Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 78, no. 1, pp. 11-19, 2008.
7. H. Chen, S. Liu, L. Ji et al., "Associations between Alzheimer's disease and blood homocysteine, vitamin B12, folate: a casecontrol study," Current Alzheimer Research, vol. 12, no. 1, pp. 88-94, 2015.
8. R. Clarke, A. D. Smith, K. A. Jobst, H. Refsum, L. Sutton, P. M. Ueland, "Folate, vitamin B12, serum total homocysteine levels in confirmed Alzheimer disease," Archives of Neurology, vol. 55, no. 11, pp. 1449-1455, 1998.
9. A. Postiglione, G. Milan, A. Ruocco, G. Gallotta, G. Guiotto, G. Di Minno, "Plasma folate, vitamin B12, total homocysteine and homozygosity for the C677Tmutation of the 5,10-methylene tetrahydrofolate reductase gene in patients with Alzheimer's dementia. A case-control study," Gerontology, vol. 47, no. 6, pp. 324-329, 2001.
10. J. A. McMahon, T. J. Green, C. M. Skeaff, R. G. Knight, J. I. Mann, S. M. Williams, "A controlled trial of homocysteine lowering and cognitive performance,"The New England Journal of Medicine, vol. 354, no. 26, pp. 2764-2772, 2006.
11. J. Durga, M. P. van Boxtel, E. G. Schouten et al., "Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial," The Lancet, vol. 369, no. 9557, pp. 208-216, 2007.
12. M. Zheng, M. Zhang, J. Yang et al., "Relationship between blood levels of methyl donor and folate and mild cognitive impairment in Chinese patients with type 2 diabetes: a casecontrol study," Journal of Clinical Biochemistry and Nutrition, vol. 54, no. 2, pp. 122-128, 2014.
13. C. R. Jack Jr., M. S. Albert,D. S. Knopman et al., "Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease," Alzheimer's and Dementia, vol. 7, no. 3, pp. 257-262, 2011.
14. F. Feng, X. Q. Han, J. Chen, L. Shang, J. Li, "Application of the activities of daily living rating scale inscreening dementia," J Clin PsycholMed, vol. 14, pp. 193-194, 2004.
15. D. Papandreou, I. Mavromichalis, A. Makedou, I. Rousso, M. Arvanitidou, "Total serumhomocysteine, folate and vitamin B12 inaGreek school agepopulation," ClinicalNutrition, vol. 25, no. 5, pp. 797-802, 2006.
16. E. P. Quinlivan, "In vitamin B12 deficiency, higher serum folate is associated with increased homocysteine and methylmalonic acid concentrations," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 5, article E7, 2008.
17. L. A. Poirier, C. K. Wise, R. R. Delongchamp, R. Sinha, "Blood determinations of S-adenosylmethionine, S-adenosylhomocysteine, homocysteine: correlations with diet," Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 6, pp. 649-655, 2001.
18. Z. Q. Sun, Medical Statistics, People'sMedical Publishing House (PMPH), Beijing, China, 2nd edition, 2013.
19. C. Ballard, M. Margallo-Lana, E. Juszczak et al., "Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial," The British Medical Journal, vol. 330, no. 7496, pp. 874-877, 2005.
20. R. J. Berry, Z. Li, J. D. Erickson et al., "Prevention of neuraltube defects with folic acid in China,"The New England Journal of Medicine, vol. 341, no. 20, pp. 1485-1490, 1999.
21. R. Schmidt, H. Schmidt, J. D. Curb, K. Masaki, L. R. White, L. J. Launer, "Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study," Annals of Neurology, vol. 52, no. 2, pp. 168-174, 2002.
22. M. J. Engelhart, M. I. Geerlings, J. Meijer et al., "Inflammatory proteins in plasma and the risk of dementia: the rotterdam study," Archives of Neurology, vol. 61, no. 5, pp. 668-672, 2004.
23. S. Das and A. Basu, "Inflammation: a new candidate in modulating adult neurogenesis," Journal of Neuroscience Research, vol. 86, no. 6, pp. 1199-1208, 2008.
24. A. L. Marsland, P. J. Gianaros, S. M. Abramowitch, S. B. Manuck, A. R. Hariri, "Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults," Biological Psychiatry, vol. 64, no. 6, pp. 484-490, 2008.
25. J. McAfoose and B. T. Baune, "Evidence for a cytokine model of cognitive function," Neuroscience and Biobehavioral Reviews, vol. 33, no. 3, pp. 355-366, 2009.
26. M. O. Chaney, J. Baudry, C. Esh et al., "A, aging, Alzheimer's disease: a tale, models, hypotheses," Neurological Research, vol. 25, no. 6, pp. 581-589, 2003.
27. B. De Strooper and G. Konig, "Alzheimer's disease: a firm base for drug development," Nature, vol. 402, no. 6761, pp. 471-472, 1999.
28. D. J. Selkoe, "Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid-protein," Annals of the New York Academy of Sciences, vol. 924, pp. 17-25, 2000.
29. M. A. Findeis, "The role of amyloid peptide 42 in Alzheimer's disease," Pharmacology andTherapeutics, vol. 116, no. 2,pp. 266-286, 2007.
30. M. Bentahir, O. Nyabi, J. Verhamme et al., "Presenilin clinical mutations can affect-secretase activity by different mechanisms," Journal of Neurochemistry, vol. 96, no. 3, pp. 732-742, 2006.
31. R. Fukuyama, T. Mizuno, T. Mizuno et al., "Age-dependent change in the levels of A40 and A42 in cerebrospinal fluid from control subjects, a decrease in the ratio of A42 to A40 level in cerebrospinal fluid from Alzheimer's disease patients," European Neurology, vol. 43, no. 3, pp. 155-160, 2000.
32. O. Hansson, H. Zetterberg, P. Buchhave et al., "Prediction of Alzheimer's disease using the CSF A42/A40 ratio in patients with mild cognitive impairment," Dementia and Geriatric Cognitive Disorders, vol. 23, no. 5, pp. 316-320, 2007.
33. K. Yaffe, A. Weston, N. R. Graff-Radford et al., "Association of plasma-amyloid level and cognitive reserve with subsequent cognitive decline," The Journal of the American Medical Association, vol. 305, no. 3, pp. 261-266, 2011.
34. T. Bottiglieri and K. Hyland, "S-adenosylmethionine levels in psychiatric and neurological disorders: a review," Acta Neurologica Scandinavica, vol. 89, supplement 154, pp. 19-26, 1994.
35. L. D. Morrison, D. D. Smith, S. J. Kish, "Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease," Journal of Neurochemistry, vol. 67, no. 3, pp. 1328-1331, 1996.
36. F. Tchantchou, M. Graves, D. Ortiz, A. Chan, E. Rogers, T. B. Shea, "S-adenosyl methionine: a connection between nutritional and genetic risk factors for neurodegeneration in Alzheimer's disease," Journal of Nutrition,Health and Aging, vol. 10, no. 6, pp. 541-544, 2006.
37. C. G. Trolin, B. Regland, L. Oreland, "Decreased methionine adenosyltransferase activity in erythrocytes of patients with dementia disorders," European Neuropsychopharmacology, vol. 5, no. 2, pp. 107-114, 1995.
38. T. Bottiglieri, P. Godfrey, T. Flynn, M. W. P. Carney, B. K. Toone, E. H. Reynolds, "Cerebrospinal fluid S-adenosylmethionine-in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine," Journal of Neurology,Neurosurgery and Psychiatry, vol. 53,no. 12,pp. 1096-1098, 1990.
39. A. C. Pfalzer, S.-W. Choi, S. A. Tammen et al., "S-adenosylmethionine mediates inhibition of inflammatory response and changes in DNA methylation in human macrophages," Physiological Genomics, vol. 46, no. 17, pp. 617-623, 2014.
40. L. Gobejishvili, D. V. Avila, D. F. Barker et al., "S-adenosylmethionine decreases lipopolysaccharide-induced phosphodiesterase 4B2 and attenuates tumor necrosis factor expression via cAMP/protein kinase A pathway," Journal of Pharmacology and Experimental Therapeutics, vol. 337, no. 2, pp. 433-443, 2011.
41. V. Purohit, M. F. Abdelmalek, S. Barve et al., "Role of Sadenosylmethionine, folate, betaine in the treatment of alcoholic liver disease: summary of a symposium," American Journal of Clinical Nutrition, vol. 86, no. 1, pp. 14-24, 2007.
42. B. Sharma and N. Singh, "Salutary effect of NFB inhibitor and folacin in hyperhomocysteinemia-hyperlipidemia induced vascular dementia," Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 38, no. 2, pp. 207-215, 2012.
43. P. J. Connelly, N. P. Prentice, G. Cousland, J. Bonham, "A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease," International Journal ofGeriatric Psychiatry, vol. 23,no. 2, pp. 155-160, 2008.
44. T.-F. Chen, R.-F. S. Huang, S.-E. Lin, J.-F. Lu, M.-C. Tang, M.-J. Chiu, "Folic acid potentiates the effect of memantine on spatial learning and neuronal protection in an Alzheimer's disease transgenic model," Journal of Alzheimer's Disease, vol. 20, no. 2, pp. 607-615, 2010.
45. T. B. Shea, J. Lyons-Weiler, E. Rogers, "Homocysteine, folate deprivation and Alzheimer neuropathology," Journal of Alzheimer's Disease, vol. 4, no. 4, pp. 261-267, 2002.
46. C. E. Creeley, D. F. Wozniak, A. Nardi, N. B. Farber, J. W. Olney, "Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain," Neurobiology of Aging, vol. 29, no. 2, pp. 153-167, 2008.
47. A. Atri, L. W. Shaughnessy, J. J. Locascio, J. H. Growdon, "Long-term course and effectiveness of combination therapy in Alzheimer disease,"AlzheimerDiseaseandAssociatedDisorders, vol. 22, no. 3, pp. 209-221, 2008.
48. O. L. Lopez, J. T. Becker, A. S. Wahed et al., "Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease," Journal ofNeurology, Neurosurgery and Psychiatry, vol. 80, no. 6, pp. 600-607, 2009.